Company intelligence / Profile preview

Phoinix Holdings

Oklahoma City, Oklahoma, United States

Ownership: Private
Development stage: Other

Overview

Phoinix Holdings is a biotechnology company focused on developing treatments for Friedreich's Ataxia (FA), a rare and progressive neurodegenerative disorder. The company's primary approach involves the use of small molecule epigenetic modifiers to increase the production of frataxin, the protein that is deficient in individuals with FA. By addressing the root genetic cause of the disease, Phoinix aims to provide a disease-modifying therapy that can improve patient outcomes. The company works closely with patient advocacy groups and academic researchers to advance its therapeutic candidates through clinical development.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Partnerships

Friedreich's Ataxia Research Alliance

Beyond the preview

Go deeper on Phoinix Holdings.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Phoinix Holdings.

Explore the full profile